With the notable exception of the anti-IgE monoclonal antibody omalizumab, early clinical trials with cytokine-targeted biologics in patients with asthma were, for the most part, disappointing ...

Dupixent (dupilumab) is a brand-name injection that’s ... Dupixent and several other biologic medications approved as add-on medications for treating asthma are recognized as treatment options ...

Enable Injections is a combination product company that is synonymous with large-volume wearable injectors. When biopharma companies want to make their biologics more convenient for patients ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

Biologic therapies are helping advance severe asthma management by targeting specific inflammatory pathways, shifting care from symptom control to potential remission, according to GlobalData.

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...

including high-concentration and high-viscosity biologics (Fig.1). The device also allows data related to drug, dosage, injection frequency and other relevant parameters to be collected ...